CLINICAL FLOW CYTOMETRY INTELLIGENCE

CFCM Intelligence

Independent analysis of clinical flow cytometry, validation, technology, AI, data and the industry behind it.

THE INTELLIGENCE BRIEFING

Research. Practice. Perspective.

Explore the latest CFCM reports and analysis, with direct access to the evidence behind them.

Newest CFCM report or editorial date first · Coverage through 7 October 2026. Source publication dates are shown separately where verified.

39 entries

CFCM DAILY RADAR

Validation & QC · AI & data · Clinical flow · Industry

CFCM Daily Radar — Synthetic Controls, EuroFlow AI, NK Clonality and CDx

Synthetic myeloma controls lead today’s radar, alongside decade-scale EuroFlow AML computation, tissue-aware NK clonality, Waters–CellCarta companion-diagnostic strategy and ESCCA measurement uncertainty guidance.

Evidence boundary. Peer-reviewed studies, professional recommendations and company announcements are labelled separately. No regulatory approval is inferred from the Waters–CellCarta partnership.

CFCM report published 7 October 2026

SUMMARY · EXTERNAL SOURCE

Standards & QC · Standards programme

NIST: CAR-T measurement and data harmonisation for AI

NIST and ISAC describe a second interlaboratory study on CD19 CAR-T phenotyping and CAR expression as nearing completion. A separate working group is developing data and metadata harmonisation and evaluation practices for AI/ML.

In context. This is work in progress, not a published CAR-T standard or approval of an AI system. The associated webinar is scheduled for 10 November 2026.

Programme reviewed in the 25 September report

SUMMARY · EXTERNAL SOURCE

Technology · Manufacturer information

Curiox: automating cocktails, FMOs and single-colour controls

Antibody Cocktailing Wizard uses an antibody-panel CSV to generate preparation protocols for the Pluto Workstation. Curiox describes automated mastermixes, fluorescence-minus-one controls and single-colour controls.

In context. These are manufacturer-described workflow capabilities. Local verification of reagent handling, cell recovery and assay performance remains necessary; this is not an independent clinical validation.

Existing product reviewed on 25 September

SUMMARY · EXTERNAL SOURCE

Regulation · European Commission programme

COMBINE Phase 2: coordinated assessment of combined studies

The European Commission's Phase 2 pilot supports a coordinated application for a medicinal-product trial combined with an IVD performance study or a medical-device investigation. The published timetable places the first Phase 2 procedures in September 2026.

In context. This is a pilot assessment procedure with eligibility criteria. It does not replace the applicable clinical-trial, MDR or IVDR requirements.

Phase 2 launched 26 June; September procedures

SUMMARY · EXTERNAL SOURCE

Technology · Manufacturer information

Ampha X30: impedance cytometry for bioprocess monitoring

Amphasys describes a label-free system that measures electrical responses of individual cells to support cell-count, viability and culture-state assessment. Its intended applications include microbial and mammalian culture monitoring.

In context. The product page describes bioprocess applications. It does not establish equivalence to a clinical immunophenotyping assay or verify a new September launch.

Existing product reviewed on 25 September

SUMMARY · EXTERNAL SOURCE

AI & data · Manufacturer announcement

Cytek adds Cloud Analysis to its digital ecosystem

Cytek announced a Cloud Analysis tool that imports experimental data from SpectroFlo and provides cloud-based analysis and storage. The announcement also introduces a Premium subscription tier.

In context. At announcement, Cloud Analysis and Premium were available in the United States. The release describes a research workflow; it does not establish EU clinical availability or independent validation.

Source published 23 September 2026

SUMMARY · EXTERNAL SOURCE

Paper: Profiling autofluorescence signatures of microplastics from commercial plastic products by flow cytometry and multivariate analysis

Tilly-Scholes et al. · Frontiers in Environmental Science · 2026

General cytometry · Peer-reviewed research

Autofluorescence as a microplastic fingerprint

A Frontiers study examines whether flow-cytometric autofluorescence can help distinguish five types of microplastic using multiple detection channels. It extends cytometry beyond labelled biological samples.

In context. Results on the tested plastics do not establish universal identification in mixed environmental samples. Matrix effects, weathering and independent identification remain important boundaries.

Source published 23 September 2026

Figure 1: microscopy images of the plastic fragments examined in the autofluorescence study.
Figure 1 · Tilly-Scholes et al.

Brightfield micrographs of the tested polymer fragments; the original scale bars and panel labels are retained.

Original paper and full caption · CC BY 4.0© 2026 Tilly-Scholes et al.. Reproduced unmodified; display size adjusted. Select the visible image for full size.
SUMMARY · EXTERNAL SOURCE

Clinical flow · Peer-reviewed research

Imaging and flow cytometry for circulating tumour cells

A study in hepatocellular carcinoma compares TruAI-assisted imaging with flow cytometry for circulating tumour-cell detection. The work places image-based and flow-based approaches alongside one another in the same disease setting.

In context. This is a study-specific comparison. It should not be read as general interchangeability of platforms or validation for every tumour type.

Source published 23 September 2026

SUMMARY · EXTERNAL SOURCE

Regulation · European Commission notice

EU GMP Annex 19 revision becomes applicable

The Commission's revised Annex 19 addresses reference and retention samples within EU Good Manufacturing Practice. The official notice gives 24 September 2026 as its applicability date.

In context. Its relevance depends on the laboratory's manufacturing and quality-system responsibilities. It is not a new universal rule for routine clinical cytometry.

Applicable from 24 September 2026

SUMMARY · EXTERNAL SOURCE

Standards & QC · Scientific meeting

NIST and NIBIB: metrology for healthcare

The NIST/NIBIB symposium brings together measurement science and healthcare applications. For cytometry, it offers context for reference materials, comparable measurements and the translation of analytical methods.

In context. A meeting programme is a sign of research priorities; it is not itself a consensus guideline, clinical recommendation or new standard.

Programme reviewed on 24 September

SUMMARY · EXTERNAL SOURCE

Clinical flow · Peer-reviewed research · abstract reviewed

Cryopreservation in receptor-occupancy assays

A Cytometry Part B study describes cryopreserving whole blood at collection for later receptor-occupancy measurement. The authors report a stability extension to 12 months and comparisons with fresh-blood measurements in the targets they tested.

In context. The public record does not support assuming that one storage strategy transfers to all targets, therapies or panels. Assay-specific validation is needed.

Included in the 23 September report

SUMMARY · EXTERNAL SOURCE

Regulation · HaDEA announcement

Joint Scientific Consultations: new EU request window

The fourth 2026 EU Joint Scientific Consultation request window runs from 23 September to 21 October. It covers eligible medicines and selected high-risk devices, including class D IVDs, to help plan evidence for later joint clinical assessment.

In context. Eligibility is specific. The announcement does not classify all flow-cytometry assays as class D or replace regulatory performance-evaluation obligations.

Source published 22 September 2026

SUMMARY · EXTERNAL SOURCE

AI & data · Preprint · not peer reviewed

Predicting AML molecular alterations from routine flow data

An interpretable multiple-instance learning preprint explores prediction of selected molecular alterations from routine AML flow-cytometry data, using discovery and independent cohorts.

In context. This is investigational prediction, not a replacement for molecular testing. Performance must be considered for each alteration, cohort and clinical decision.

Preprint submitted 16 September 2026

SUMMARY · EXTERNAL SOURCE

Clinical flow · Guidance publication

ICSH guidance on bone-marrow examination and reporting

Updated ICSH guidance brings morphology, flow cytometry, immunohistochemistry and molecular genetics together in integrated bone-marrow reporting. It refines the 2008 recommendations in the context of current classification systems.

In context. Read the full recommendations and their scope before changing local practice. An editorial summary cannot replace the guideline or the laboratory's validation and governance.

Included in the 22 September report

SUMMARY · EXTERNAL SOURCE

General cytometry · Peer-reviewed research

Code-multiplexed impedance cytometry and deep unfolding

A Microsystems & Nanoengineering paper combines multi-frequency impedance cytometry with a deep-unfolding network for signal reconstruction. It illustrates a route toward extracting richer electrical information from cells.

In context. This is an engineering study. Its reported device and modelling performance should not be extrapolated directly to clinical diagnostic utility.

Included in the 21 September report

CFCM illustration
  1. 1. Acquire electrical measurements
  2. 2. Reconstruct overlapping signals
  3. 3. Evaluate on independent samples
Conceptual CFCM data-workflow illustration; not a reproduction of the paper’s device figure.
SUMMARY · EXTERNAL SOURCE

Regulation · European Commission guidance

MDCG classification guidance: revision 5

The Commission published revision 5 of MDCG 2020-16, the guidance on IVDR classification rules. This is the primary document to consult when reviewing classification reasoning, including the Rule 7 discussion already tracked in CFCM.

In context. Guidance is applied to the specific intended purpose and regulatory context. A reagent, instrument and complete assay must not be treated as automatically having the same classification.

Source published 9 September 2026

SUMMARY · EXTERNAL SOURCE

Technology · Manufacturer announcement

ViaComp Ultra XT: synthetic controls for unmixing and viability

Slingshot Bio describes a cell-mimic control intended to support compensation or spectral unmixing together with viability-dye workflows. Its announcement distinguishes versions for different viability-dye chemistries.

In context. The launch was on 17 August, not in the September report week. Claims come from the manufacturer and do not establish universal equivalence to biological assay controls.

Source published 17 August 2026

SUMMARY · EXTERNAL SOURCE

Clinical flow · Peer-reviewed research · abstract reviewed

CD71-positive immature red cells in PNH analysis

A study evaluates CD71-based immature-red-cell analysis alongside leukocyte PNH clone measurements. The authors report improved correlation and delineation of red-cell clone types in their study.

In context. This is an additional analytical approach to assess in context, not a reason to replace established multi-lineage PNH testing without validation.

Included in the 20 September report

SUMMARY · EXTERNAL SOURCE

AI & data · Peer-reviewed research

ConvexGating: interpretable gates from cell clusters

ConvexGating translates cell-cluster information into hierarchical gating strategies. The Nature Communications study evaluates the approach as a way to make computationally identified populations accessible through interpretable gates.

In context. The gates depend on the input data and target populations. Clinical use still needs assay-specific evaluation; an algorithmic benchmark is not clinical approval.

Source published 18 September 2026

CFCM illustration
  1. 1. Define the target population
  2. 2. Propose an interpretable gate
  3. 3. Test recovery and contamination
Conceptual CFCM evaluation path; not a reproduction of the paper’s Figure 1.
SUMMARY · EXTERNAL SOURCE

Clinical flow · Source summary

Real-world MM-MRD: feasibility and immune correlates

A single-centre study examines implementation of a standardised flow-cytometric MRD workflow in multiple myeloma, its clinical implications and immune correlates. Feasibility in that setting does not establish a transferable MRD detection limit for every laboratory.

Recorded CFCM editorial date

SUMMARY · EXTERNAL SOURCE

Paper: A standardized single-tube 17-color spectral flow cytometry workflow for integrated immunophenotyping of human PBMCs and mixed co-culture systems

Kiel et al. · Frontiers in Immunology · 2026

Standards & QC · Source summary

Standardising a 17-Colour Spectral Workflow

Peer-reviewed methods · A defined 17-colour PBMC/co-culture workflow. This is not validation of every spectral panel or a clinical MRD assay.

Recorded CFCM editorial date

Figure 1: a branching overview of the leukocyte populations and functional markers in the 17-colour workflow.
Figure 1 · Kiel et al.

An overview of the immune-cell hierarchy and markers covered by the 17-colour panel.

Original paper and full caption · CC BY 4.0© 2026 Kiel et al.. Reproduced unmodified; display size adjusted. Select the visible image for full size.
SUMMARY · EXTERNAL SOURCE

Clinical flow · Source summary

Cells vs Beads vs CaptureBody

Peer-reviewed methods · CaptureBody links anti-CD45 and anti-IgG to create cell-based reference controls. The 31 August 2026 journal publication supersedes the February preprint; suitability remains reagent- and workflow-dependent.

Recorded CFCM editorial date

SUMMARY · EXTERNAL SOURCE

Paper: Superior precision of clinical predictions after CD3-relativisation to align flow cytometry data

Glehr et al. · eBioMedicine · 2026

Clinical flow · Source summary

Can the Cells Themselves Calibrate Across Instruments?

Peer-reviewed study · CD3-relativisation was evaluated with 482 samples from 381 healthy donors and 100 post-surgical ICU samples, using six cytometers at four laboratories. This tests data alignment; it does not replace instrument QC or prove universal clinical equivalence.

Recorded CFCM editorial date

Figure 1: CD3 positive and negative reference signals define a transformation to align fluorescence measurements across cytometers.
Figure 1 · Glehr et al.

CD3-positive and negative reference signals define the transformation illustrated with measurements from two cytometers.

Original paper and full caption · CC BY 4.0© 2026 Glehr et al.. Reproduced unmodified; display size adjusted. Select the visible image for full size.
SUMMARY · CFCM RESOURCE

Technology · Source summary

Spectral Similarity Is Not Enough

CFCM technical analysis · Evaluate spreading and the resolution of the final marker combinations as well as spectral similarity. A similarity score alone is not a clinical acceptance criterion.

Recorded CFCM editorial date

SUMMARY · EXTERNAL SOURCE

Clinical flow · Source summary

MRD Moves Closer to a Drug-Development Endpoint

Regulatory record · On 13 August 2026, the FDA granted accelerated approval to an iberdomide combination using MRD-negative complete response as the major efficacy outcome. This does not establish interchangeability of all MRD assays.

Recorded CFCM editorial date

SUMMARY · EXTERNAL SOURCE

Standards & QC · Source summary

Measurement Uncertainty in ISO 15189 Flow Laboratories

Consensus / recommendations · Johansson and colleagues' ESCCA paper, published 28 August 2026, describes a risk-based approach to process variability. It is guidance, not a patient cohort establishing a universal uncertainty target.

Recorded CFCM editorial date

SUMMARY · EXTERNAL SOURCE

AI & data · Source summary

NeutroFlow, PRISM and AI Beyond Conventional Gating

Research projects · CORDIS describes NeutroFlow biomarker development and PRISM physics-aware unmixing research. Project objectives are not completed clinical-validation results or regulatory approval.

Recorded CFCM editorial date

CFCM ARTICLE

Paper: Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers

Rietdijk et al. · Frontiers in Immunology · 2026

Technology · CFCM analysis

The 40-Colour Race May Be Ending

Very high-parameter panels are technically impressive, but clinical value increasingly depends on standardisation, reproducibility and interpretable workflow design.

Recorded CFCM editorial date

Figure 1: sequential clean-up, singlet, CD45 and live-cell gates for the published immune-profiling workflow.
Figure 1 · Rietdijk et al.

Data cleaning and sequential singlet, CD45 and viability gates; a representative healthy-donor sample.

Original paper and full caption · CC BY 4.0© 2026 Rietdijk et al.. Reproduced unmodified; display size adjusted. Select the visible image for full size.
CFCM ARTICLE

Clinical flow · CFCM analysis

The Best CD38 Antibody Depends on the Therapy

Anti-CD38 therapy changes the analytical problem: clone choice must be validated against treatment context.

Recorded CFCM editorial date

CFCM ARTICLE

Clinical flow · CFCM analysis

Flow Cytometry as a Cell-Therapy Release Assay

Cell and gene therapy may be one of the clearest growth areas for high-value validated flow workflows.

Recorded CFCM editorial date

CFCM ARTICLE

Clinical flow · CFCM analysis

Your Treatment Can Break Your MRD Panel

Therapy can alter antigen expression enough to invalidate assumptions built into an MRD panel.

Recorded CFCM editorial date

CFCM ARTICLE

Standards & QC · CFCM analysis

Can Spectral AML MRD Be Standardised Across Multiple Centres?

The unit of validation is the full network, not the cytometer alone.

Recorded CFCM editorial date

CFCM ARTICLE

Standards & QC · CFCM analysis

Synthetic Controls, Spectral MRD and Reproducibility

Controls matter when they reduce variability across time, sites and instruments.

Recorded CFCM editorial date

CFCM ARTICLE

AI & data · CFCM analysis

DinoFlow: Is Flow Cytometry Getting a Foundation Model?

Reusable representation learning could change how cytometry AI is built and validated.

Recorded CFCM editorial date

CFCM ARTICLE

AI & data · CFCM analysis

Deep Learning for Mature B-Cell Neoplasms Reaches Clinical-Scale Data

The next question is not classification alone, but interpretability, monitoring and failure handling.

Recorded CFCM editorial date

CFCM ARTICLE

AI & data · CFCM analysis

Can an LLM Choose the Right Flow Panel?

Clinical panel selection points toward hybrid AI: language models plus deterministic safety constraints.

Recorded CFCM editorial date

CFCM ARTICLE

Regulation · CFCM analysis

Clinical Flow AI Under the EU AI Act

Accuracy is only one part of clinical AI: intended use, risk, oversight and lifecycle evidence matter.

Recorded CFCM editorial date

CFCM ARTICLE

Technology · CFCM analysis

Chinese Spectral Cytometry Arrives in Europe

Evidence quality, regulatory positioning and local support will determine adoption.

Recorded CFCM editorial date

CFCM ARTICLE

Technology · CFCM analysis

Has Clinical Spectral Flow Cytometry Finally Arrived?

MRD, spectral-plus-imaging and AI-assisted analysis are converging toward clinical use.

Recorded CFCM editorial date